 "Lupin gets USFDA nod for marketing testosterone topical solution")
Drug firm Lupin on Wednesday said it has received the final approval from the US health regulator for its testosterone topical solution.
The company has received final approval for its testosterone topical solution, 30 mg per actuation from the United States Food and Drug Administration (USFDA) to market the product, Lupin said in a BSE filing.
The approved product is a generic version of Eli Lilly and Company's Axiron topical solution, it added.
According to IMS MAT June 2017 data, testosterone topical solution had sales of $244.2 million in the US, Lupin said.
The testosterone topical solution are indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone, it added.
Shares of Lupin were trading at Rs 1028.50, up 0.19 per cent from the previous close on BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%